Skip to content
Screener

Discontinued — last reported Q2 '26

Operating Income at other companies

Illumina logo
IlluminaILMN
$245M+14.5%
Quanterix Corporation logo
Quanterix CorporationQTRX
-$49.43M-33.2%
Revvity logo
RevvityRVTY
$89.32M-1.6%
Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
-$45.86M-10.4%
Agilent Technologies logo
Agilent TechnologiesA
$399M+33.0%
Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
-$12.32M-1.4%

Other financials

Income statement

See full
Revenue$39.0M-1.9%
Gross profit$12.6M-13.9%
Net income-$44.7M-6.7%
EPS (diluted)-$0.140.0%

Balance sheet

See full
Cash & equivalents$62.6M+10.5%
Total debt$61.8M+17.1%
Total equity-$33.2M-154%
Total assets$751.9M-8.9%

Cash flow

See full
Operating cash flow-$35.6M-21.1%
CapEx$1.6M+183%
Free cash flow-$37.1M-24.1%

Valuation

See full
Market cap$368.06M-5.6%
Enterprise value$367.25M-4.8%
P/S2.3×-0.2×

Profitability

See full
Gross margin36.4%+15.0pp
Operating margin-83.5%-37.4pp
Net margin-82.5%-35.5pp
FCF margin-77.5%-13.2pp

Returns & leverage

See full
Return on equity-273.6%+314pp
Debt / equity25.1×+24.5×
Current ratio4.9×-2.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Pacific Biosciences of California’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:30 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001299130-26-000122
(In thousands, except per share amounts)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Amortization of acquired intangible assets8338331,666362,875
Change in fair value of contingent consideration(18,700)
Total operating expense57,24859,53778,446487,100
Operating loss(44,610)(44,853)(52,967)(473,787)
Interest expense(2,110)(1,738)(3,850)(3,475)
Other income, net2,0374,6964,0438,990
Loss before income taxes(44,683)(41,895)(52,774)(468,272)
Income tax provision (benefit)5835242(267)

Item 1. Financial Statements (unaudited):

FAQ

What is Pacific Biosciences of California's operating income?
Pacific Biosciences of California (PACB) reported operating income of -$44.61M in Q2 2026.
How has Pacific Biosciences of California's operating income changed year-over-year?
Pacific Biosciences of California's operating income increased by 0.5% year-over-year, from -$44.85M to -$44.61M.
What is the long-term trend for Pacific Biosciences of California's operating income?
Over 4 years (2021 to 2025), Pacific Biosciences of California's operating income has grown at a 27.4% compound annual growth rate (CAGR), from -$210.44M to -$553.86M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Pacific Biosciences of California's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude